The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.

SUPER-1 evaluated GZR4 in insulin-naïve Chinese adults with T2DM, while SUPER-2 assessed those previously treated with basal insulin.

Insulin pumps can help people with diabetes manage their blood sugar levels. The small, wearable electronic device gives predetermined rates of insulin to your body. You may want to use an insulin ...

You can manage type 2 diabetes several ways, including with a healthy diet and regular exercise. But sometimes, you may need insulin and other medication to help control your blood sugar levels. The ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S’ NVO Awiqli (insulin icodec-abae), marking ...

Late last week, medical device giant Medtronic received FDA approval for its MiniMed 780G system. The device is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...